172 related articles for article (PubMed ID: 23015261)
1. Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence.
Smith CL; Migliaccio I; Chaubal V; Wu MF; Pace MC; Hartmaier R; Jiang S; Edwards DP; Gutiérrez MC; Hilsenbeck SG; Oesterreich S
Breast Cancer Res Treat; 2012 Nov; 136(1):253-65. PubMed ID: 23015261
[TBL] [Abstract][Full Text] [Related]
2. The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity.
Peterson TJ; Karmakar S; Pace MC; Gao T; Smith CL
Mol Cell Biol; 2007 Sep; 27(17):5933-48. PubMed ID: 17591692
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells.
Hong W; Chen L; Li J; Yao Z
Biochem Biophys Res Commun; 2010 May; 396(2):299-303. PubMed ID: 20406620
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
Keeton EK; Brown M
Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
[TBL] [Abstract][Full Text] [Related]
5. Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor.
Karmakar S; Gao T; Pace MC; Oesterreich S; Smith CL
Mol Endocrinol; 2010 Jun; 24(6):1187-202. PubMed ID: 20392877
[TBL] [Abstract][Full Text] [Related]
6. SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERα transcriptional activity.
Zhang L; Gong C; Lau SL; Yang N; Wong OG; Cheung AN; Tsang JW; Chan KY; Khoo US
Cancer Res; 2013 Jan; 73(1):246-55. PubMed ID: 23117886
[TBL] [Abstract][Full Text] [Related]
7. G protein pathway suppressor 2 (GPS2) is a transcriptional corepressor important for estrogen receptor alpha-mediated transcriptional regulation.
Cheng X; Kao HY
J Biol Chem; 2009 Dec; 284(52):36395-36404. PubMed ID: 19858209
[TBL] [Abstract][Full Text] [Related]
8. The SMRT coregulator enhances growth of estrogen receptor-α-positive breast cancer cells by promotion of cell cycle progression and inhibition of apoptosis.
Blackmore JK; Karmakar S; Gu G; Chaubal V; Wang L; Li W; Smith CL
Endocrinology; 2014 Sep; 155(9):3251-61. PubMed ID: 24971610
[TBL] [Abstract][Full Text] [Related]
9. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
10. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
11. BQ323636.1, a Novel Splice Variant to
Gong C; Man EPS; Tsoi H; Lee TKW; Lee P; Ma ST; Wong LS; Luk MY; Rakha EA; Green AR; Ellis IO; Lam EW; Cheung KL; Khoo US
Clin Cancer Res; 2018 Aug; 24(15):3681-3691. PubMed ID: 29420220
[No Abstract] [Full Text] [Related]
12. Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer.
Nisman B; Allweis TM; Carmon E; Kadouri L; Maly B; Maimon O; Meierovich A; Peretz T
Anticancer Res; 2020 Nov; 40(11):6417-6428. PubMed ID: 33109580
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
14. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
van Agthoven T; Sieuwerts AM; Veldscholte J; Meijer-van Gelder ME; Smid M; Brinkman A; den Dekker AT; Leroy IM; van Ijcken WF; Sleijfer S; Foekens JA; Dorssers LC
Br J Cancer; 2009 Dec; 101(11):1824-32. PubMed ID: 19904269
[TBL] [Abstract][Full Text] [Related]
15. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
[TBL] [Abstract][Full Text] [Related]
16. Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer.
Chan CM; Lykkesfeldt AE; Parker MG; Dowsett M
Clin Cancer Res; 1999 Nov; 5(11):3460-7. PubMed ID: 10589759
[TBL] [Abstract][Full Text] [Related]
17. A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer.
Cao L; Xiang G; Liu F; Xu C; Liu J; Meng Q; Lyu S; Wang S; Niu Y
Cancer Chemother Pharmacol; 2019 Sep; 84(3):609-620. PubMed ID: 31297554
[TBL] [Abstract][Full Text] [Related]
18. [Expression of ER alpha and SMRT in apoptosis of breast cancer cells induced by tamoxifen].
Zhao XH; Wang ZY; Li LL
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2008 May; 37(3):276-82. PubMed ID: 18546531
[TBL] [Abstract][Full Text] [Related]
19. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel ER-alpha target genes in breast cancer cells: gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17beta-estradiol and tamoxifen.
Romano A; Adriaens M; Kuenen S; Delvoux B; Dunselman G; Evelo C; Groothuis P
Mol Cell Endocrinol; 2010 Jan; 314(1):90-100. PubMed ID: 19698761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]